Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company, has announced multiple scientific presentations on its clinical pipeline at the ARVO 2023 Annual Meeting in New Orleans from April 23-27, 2023. Key presentations will include data on tarcocimab tedromer (KSI-301) and KSI-501, focusing on their effectiveness in treating retinal diseases. Victor Perlroth, CEO of Kodiak, emphasized their commitment to advancing therapeutics targeting high-prevalence retinal diseases. The company is conducting Phase 3 studies for tarcocimab and a Phase 1 study for KSI-501. The results from these studies are pivotal, with topline data expected in 3Q2023, potentially leading to a single Biologics Licensing Application for multiple indications.
Kodiak Sciences Inc. (Nasdaq: KOD) announced the initiation of a Phase 1 clinical study for KSI-501, an investigational bispecific antibody biopolymer conjugate, designed to treat diabetic macular edema (DME). The study, conducted in the USA, aims to evaluate the safety and maximum tolerated dose of KSI-501. This product targets both vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), addressing inflammatory components in retinal diseases. The ABC Platform utilized for KSI-501 may provide unique therapeutic benefits, including extended durability. Kodiak's ongoing research aims to broaden treatment options in retinal diseases, anticipating future insights from the study.
Kodiak Sciences Inc. (KOD) reported Q4 2022 results, highlighting a net loss of $70.4 million, or $1.35 per share, an improvement from $93.2 million, or $1.79 per share, in Q4 2021. R&D expenses decreased to $56 million from $75.6 million, attributed to the maturation of the tarcocimab program. The company holds $478.9 million in cash and equivalents. Key upcoming events include topline data from four Phase 3 studies set for Q3 2023. Kodiak is also advancing KSI-501, a bispecific antibody, expected to enter clinical testing. The firm aims to enhance its market position in retinal diseases with innovative therapies.
Kodiak Sciences Inc. (Nasdaq: KOD) announced a presentation scheduled for February 11, 2023, at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting, focusing on clinical data for its investigational therapy KSI-301 (tarcocimab tedromer) and updates on its Antibody Biopolymer Conjugate (ABC) development programs. CEO Victor Perlroth highlighted the progress with KSI-301, anticipating four Phase 3 clinical study readouts in Q3 2023. Additionally, the company has successfully opened an Investigational New Drug (IND) application for KSI-501, a bispecific therapy aimed at retinal diseases, with a Phase 1 study set to begin shortly.